Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Asston Pharmaceuticals Ltd. shows no growth metrics and lacks profitability indicators like ROE, ROA, and EBITDA margins, positioning it as a laggard in the sector. In contrast, peers such as Sun Pharmaceutical and Dr. Reddy's Laboratories demonstrate strong growth, profitability, and efficient capital utilization, while others like Divi's Laboratories struggle with declining revenues.
Highest revenue growth YoY (8.42%) and 3-Year EPS growth (45.55).
Strong profitability with a ROE of 21.76% and solid revenue growth (16.54% YoY).